Long-term β-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study

Korean study (n=28,970) found that compared with patients receiving β-blocker therapy for <1 year, those receiving therapy for ≥1 year had significantly lower risks of all-cause death [adjusted hazard ratio 0.81; 95% CI 0.72–0.91].


European Heart Journal